EDAP TMS | EDAP

EDAP TMS traded at $11.50 this Wednesday March 22nd, increasing $0.27 or 2.40 percent since the previous trading session. Looking back, over the last four weeks, EDAP TMS gained 3.85 percent. Over the last 12 months, its price rose by 59.94 percent. Looking ahead, we forecast EDAP TMS to be priced at 10.49 by the end of this quarter and at 9.54 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
11.50
Daily Change
2.40%
Yearly
59.94%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AngioDynamics 12.34 -0.11 -0.88% -43.26%
Boston Scientific 48.69 -0.16 -0.32% 15.09%
Plus Therapeutics, Inc. 0.28 0.01 2.75% -72.82%
EDAP TMS 11.50 0.27 2.40% 59.94%
Henry Schein 79.86 -0.38 -0.47% -9.05%
Medtronic 81.11 -0.12 -0.15% -23.60%
Sientra 1.50 0.02 1.34% -39.03%
Veracyte 22.70 -0.54 -2.32% -15.71%

Indexes Price Day Year
USND 11847 -12.71 -0.11% -14.91%

EDAP TMS
EDAP TMS S.A. (EDAP) is a company that develops, manufactures, promotes and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology. The Company operates worldwide via an extensive network of corporate offices, subsidiaries and distribution partners. The Company invests in Research & Development, partnering with INSERM French public laboratory and international medical research institutions. Company's activity is organized in two divisions: HIFU and UDS (including lithotripsy activities). The Company is developing HIFU technology (High Intensity Focused Ultrasound) in non-invasive treatment of prostate conditions with its range of Robotic HIFU devices, Ablatherm Fusion and Focal One. The Company is also developing ESWL (Extracorporeal ShockWave Lithotripsy) and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications.